FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an open label single arm prospective multicenter Phase II study in around 20
patients. The primary objective of this study is to evaluate whether the addition of
sunitinib to FOLFIRI results in a significant reduction of tumor vessel permeability (TVP)
and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.
Secondary objectives are antitumor response, time to progression (TTP), effect on
pharmacokinetics of sunitinib and biomarkers (VEGF und soluble VEGF-receptor) and
drug/treatment safety.
Phase:
Phase 2
Details
Lead Sponsor:
Central European Society for Anticancer Drug Research